{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:41:20Z","timestamp":1790876480113,"version":"4.1.0"},"reference-count":121,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,2,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with historically poor outcomes and no worldwide consensus treatment approach. Unique among most hematologic malignancies for its frequent cutaneous involvement, BPDCN can also invade other extramedullary compartments, including the central nervous system. Generally affecting older adults, many patients are unfit to receive intensive chemotherapy, and although hematopoietic stem cell transplantation is preferred for younger, fit individuals, not all are eligible. One recent therapeutic breakthrough is that all BPDCNs express CD123 (IL3R\u03b1) and that this accessible surface marker can be pharmacologically targeted. The first-in-class agent for BPDCN, tagraxofusp, which targets CD123, was approved in December 2018 in the United States for patients with BPDCN aged \u22652 years. Despite favorable response rates in the frontline setting, many patients still relapse in the setting of monotherapy, and outcomes in patients with relapsed\/refractory BPDCN remain dismal. Therefore, novel approaches targeting both CD123 and other targets are actively being investigated. To begin to formally address the state of the field, we formed a new collaborative initiative, the North American BPDCN Consortium (NABC). This group of experts, which includes a multidisciplinary panel of hematologists\/oncologists, hematopoietic stem cell transplant physicians, pathologists, dermatologists, and pediatric oncologists, was tasked with defining the current standard of care in the field and identifying the most important research questions and future directions in BPDCN. The position findings of the NABC\u2019s inaugural meetings are presented herein.<\/jats:p>","DOI":"10.1182\/blood.2022017865","type":"journal-article","created":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T16:16:20Z","timestamp":1668788180000},"page":"567-578","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":63,"title":["North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need"],"prefix":"10.1182","volume":"141","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1670-6513","authenticated-orcid":false,"given":"Naveen","family":"Pemmaraju","sequence":"first","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendra","family":"Sweet","sequence":"additional","affiliation":[{"name":"2Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice","family":"Wang","sequence":"additional","affiliation":[{"name":"3Roswell Park Comprehensive Cancer Center, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6831-2567","authenticated-orcid":false,"given":"Jayastu","family":"Senapati","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel R.","family":"Wilson","sequence":"additional","affiliation":[{"name":"4Department of Internal Medicine, The University of Texas School of Health Sciences at Houston, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9347-2212","authenticated-orcid":false,"given":"Marina","family":"Konopleva","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur E.","family":"Frankel","sequence":"additional","affiliation":[{"name":"5West Palm Beach VA Medical Center, West Palm Beach, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1419-8607","authenticated-orcid":false,"given":"Vikas","family":"Gupta","sequence":"additional","affiliation":[{"name":"6MPN Program, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Mesa","sequence":"additional","affiliation":[{"name":"7Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Ulrickson","sequence":"additional","affiliation":[{"name":"8Banner MD Anderson Cancer Center, Gilbert, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Gorak","sequence":"additional","affiliation":[{"name":"9Baptist MD Anderson Cancer Center, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumeet","family":"Bhatia","sequence":"additional","affiliation":[{"name":"10Community Health Network, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6498-9119","authenticated-orcid":false,"given":"Tulin","family":"Budak-Alpdogan","sequence":"additional","affiliation":[{"name":"11Department of Hematology, MD Anderson Cancer Center at Cooper, Cooper Health University, Camden, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Mason","sequence":"additional","affiliation":[{"name":"12Scripps MD Anderson Cancer Center, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1408-8109","authenticated-orcid":false,"given":"Maria Teresa","family":"Garcia-Romero","sequence":"additional","affiliation":[{"name":"13Department of Dermatology, National Pediatrics Institute, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norma","family":"Lopez-Santiago","sequence":"additional","affiliation":[{"name":"14Division of Hematology\/Oncology, Hematology Service, National Pediatrics Institute, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8397-0330","authenticated-orcid":false,"given":"Gabriela","family":"Cesarman-Maus","sequence":"additional","affiliation":[{"name":"15Department of Hematology, Instituto Nacional de Cancerolog\u00eda, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9779-6217","authenticated-orcid":false,"given":"Pankit","family":"Vachhani","sequence":"additional","affiliation":[{"name":"16O'Neal Comprehensive Cancer Center at UAB, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangmin","family":"Lee","sequence":"additional","affiliation":[{"name":"17Division of Hematology and Oncology, Department of Medicine, Clinical and Translational Leukemia Program, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2513-0533","authenticated-orcid":false,"given":"Vijaya Raj","family":"Bhatt","sequence":"additional","affiliation":[{"name":"18The Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Blum","sequence":"additional","affiliation":[{"name":"19Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9268-3341","authenticated-orcid":false,"given":"Roland B.","family":"Walter","sequence":"additional","affiliation":[{"name":"20Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale","family":"Bixby","sequence":"additional","affiliation":[{"name":"21Department of Hematology\/Oncology, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Gojo","sequence":"additional","affiliation":[{"name":"22Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Duvic","sequence":"additional","affiliation":[{"name":"23Division of Internal Medicine, Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raajit K.","family":"Rampal","sequence":"additional","affiliation":[{"name":"24Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"de Lima","sequence":"additional","affiliation":[{"name":"25Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Foran","sequence":"additional","affiliation":[{"name":"26Department of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4907-6447","authenticated-orcid":false,"given":"Amir T.","family":"Fathi","sequence":"additional","affiliation":[{"name":"27Harvard Medical School, Leukemia Program, Medicine, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6520-6056","authenticated-orcid":false,"given":"Aric Cameron","family":"Hall","sequence":"additional","affiliation":[{"name":"28Division of Hematology, Medical Oncology and Palliative Care, University of Wisconsin School of Medicine and Public Health, Madison, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meagan A.","family":"Jacoby","sequence":"additional","affiliation":[{"name":"29Department of Medicine, Washington University Medical School, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Lancet","sequence":"additional","affiliation":[{"name":"2Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Mannis","sequence":"additional","affiliation":[{"name":"30Division of Hematology, Department of Medicine, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony S.","family":"Stein","sequence":"additional","affiliation":[{"name":"31Department of Hematology\/Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8971-2199","authenticated-orcid":false,"given":"Alice","family":"Mims","sequence":"additional","affiliation":[{"name":"32Wexner Medical Center, James Cancer Hospital, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9886-5771","authenticated-orcid":false,"given":"David","family":"Rizzieri","sequence":"additional","affiliation":[{"name":"33Novant Health Cancer Institute, Winston Salem, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Olin","sequence":"additional","affiliation":[{"name":"34Division of Hematology\/Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1463-2231","authenticated-orcid":false,"given":"Alexander","family":"Perl","sequence":"additional","affiliation":[{"name":"35Division of Hematology-Oncology, Perelman School of Medicine at the University of Pennsylvania, Abramson Cancer Center, Leukemia Program, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Schiller","sequence":"additional","affiliation":[{"name":"36Division of Hematology-Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Shami","sequence":"additional","affiliation":[{"name":"37Huntsman Cancer Institute, University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M.","family":"Stone","sequence":"additional","affiliation":[{"name":"38Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6861-2041","authenticated-orcid":false,"given":"Stephen","family":"Strickland","sequence":"additional","affiliation":[{"name":"39Vanderbilt-Ingram Cancer Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Wieduwilt","sequence":"additional","affiliation":[{"name":"40Division of Bone Marrow Transplantation, Moores Cancer Center, University of California San Diego, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7103-373X","authenticated-orcid":false,"given":"Naval","family":"Daver","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumithira","family":"Vasu","sequence":"additional","affiliation":[{"name":"41Division of Hematology, Bone Marrow Transplantation and Cellular Therapies Program, The Ohio State University James Cancer Hospital, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9262-8246","authenticated-orcid":false,"given":"Monica","family":"Guzman","sequence":"additional","affiliation":[{"name":"42Division of Hematology and Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0384-3658","authenticated-orcid":false,"given":"Gail J.","family":"Roboz","sequence":"additional","affiliation":[{"name":"43Division of Hematology and Medical Oncology, Leukemia Program, Weill Cornell Medicine\/New York-Presbyterian Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2621-3584","authenticated-orcid":false,"given":"Joseph","family":"Khoury","sequence":"additional","affiliation":[{"name":"44Division of Pathology\/Lab Medicine, Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muzaffar","family":"Qazilbash","sequence":"additional","affiliation":[{"name":"45Division of Cancer Medicine, Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3398-0573","authenticated-orcid":false,"given":"Phyu P.","family":"Aung","sequence":"additional","affiliation":[{"name":"46Division of Pathology\/Lab Medicine, Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branko","family":"Cuglievan","sequence":"additional","affiliation":[{"name":"47Division of Pediatrics, Department of Pediatrics Patient Care, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9573-2690","authenticated-orcid":false,"given":"Yazan","family":"Madanat","sequence":"additional","affiliation":[{"name":"48UT Southwestern Harold C. Simmons Comprehensive Cancer Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7394-5185","authenticated-orcid":false,"given":"Mohamed A.","family":"Kharfan-Dabaja","sequence":"additional","affiliation":[{"name":"26Department of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9466-6396","authenticated-orcid":false,"given":"Anna","family":"Pawlowska","sequence":"additional","affiliation":[{"name":"49Department of Pediatrics, Pediatric HCT Program, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4407-6325","authenticated-orcid":false,"given":"Justin","family":"Taylor","sequence":"additional","affiliation":[{"name":"50Division of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Tallman","sequence":"additional","affiliation":[{"name":"51Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, Manhattan, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2368-1510","authenticated-orcid":false,"given":"Prajwal","family":"Dhakal","sequence":"additional","affiliation":[{"name":"52Leukemia, University of Iowa, Iowa City, IA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7380-0226","authenticated-orcid":false,"given":"Andrew A.","family":"Lane","sequence":"additional","affiliation":[{"name":"38Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2023082817145354300_bib1","first-page":"58","article-title":"Incidence and characteristics of CD4(+)\/HLA DRhi dendritic cell malignancies","volume":"89","author":"Bueno","year":"2004","journal-title":"Haematologica"},{"issue":"1","key":"2023082817145354300_bib2","first-page":"143","article-title":"Primary cutaneous CD4+\/CD56+ hematodermic neoplasm (blastic NK-cell lymphoma): a report of five cases","volume":"91","author":"Ng","year":"2006","journal-title":"Haematologica"},{"issue":"2","key":"2023082817145354300_bib3","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3324\/haematol.2012.072645","article-title":"GIMEMA-ALWP (Gruppo Italiano Malattie EMatologiche dell\u2019Adulto, A. L. W. P. blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian Multicenter Study","volume":"98","author":"Pagano","year":"2013","journal-title":"Haematologica"},{"key":"2023082817145354300_bib4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.leukres.2018.08.014","article-title":"Epidemiology and survival of blastic plasmacytoid dendritic cell neoplasm","volume":"73","author":"Guru Murthy","year":"2018","journal-title":"Leuk Res"},{"issue":"22","key":"2023082817145354300_bib5","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.4789.4789","article-title":"Blastic plasmacytoid dendritic cell neoplasm. a population-based analysis from the SEER and NCDB databases [abstract]","volume":"128","author":"Alsidawi","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2023082817145354300_bib6","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1182\/blood.V99.5.1556","article-title":"Clinical and biologic features of CD4(+)CD56(+) malignancies","volume":"99","author":"Feuillard","year":"2002","journal-title":"Blood"},{"issue":"3","key":"2023082817145354300_bib7","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.hoc.2020.01.002","article-title":"Molecular features of blastic plasmacytoid dendritic cell neoplasm: DNA mutations and epigenetics","volume":"34","author":"Sapienza","year":"2020","journal-title":"Hematol Oncol Clin N Am"},{"issue":"20","key":"2023082817145354300_bib8","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"7","key":"2023082817145354300_bib9","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th\u00a0edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"2","key":"2023082817145354300_bib10","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/bjh.14146","article-title":"Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches","volume":"174","author":"Pagano","year":"2016","journal-title":"Br J Haematol"},{"issue":"7","key":"2023082817145354300_bib11","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.bbmt.2013.01.027","article-title":"Diagnostic and therapeutic advances in blastic plasmacytoid dendritic cell neoplasm: a focus on hematopoietic cell transplantation.","volume":"19","author":"Kharfan-Dabaja","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2023082817145354300_bib12","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.bbmt.2016.03.022","article-title":"Blastic plasmacytoid dendritic cell neoplasm: from origin of the cell to targeted therapies","volume":"22","author":"Laribi","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2023082817145354300_bib13","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3390\/cancers11050595","article-title":"Blastic plasmacytoid dendritic cell neoplasm: state of the art and prospects","volume":"11","author":"Sapienza","year":"2019","journal-title":"Cancers"},{"issue":"24","key":"2023082817145354300_bib14","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1182\/bloodadvances.2019000647","article-title":"How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?","volume":"3","author":"Garnache-Ottou","year":"2019","journal-title":"Blood Adv"},{"issue":"12","key":"2023082817145354300_bib15","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/ajh.23567","article-title":"TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow","volume":"88","author":"Alayed","year":"2013","journal-title":"Am J Hematol"},{"issue":"15","key":"2023082817145354300_bib16","doi-asserted-by":"crossref","first-page":"6404","DOI":"10.18632\/oncotarget.2223","article-title":"Targeted ultra-deep sequencing reveals recurrent and mutually exclusive mutations of cancer genes in blastic plasmacytoid dendritic cell neoplasm","volume":"5","author":"Stenzinger","year":"2014","journal-title":"Oncotarget"},{"key":"2023082817145354300_bib17","doi-asserted-by":"crossref","first-page":"102928","DOI":"10.1016\/j.critrevonc.2020.102928","article-title":"New perspectives in genetics and targeted therapy for blastic plasmacytoid dendritic cell neoplasm","volume":"149","author":"Zhang","year":"2020","journal-title":"Crit Rev Oncol-Hematol"},{"issue":"2","key":"2023082817145354300_bib18","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1158\/2159-8290.CD-20-1513","article-title":"Sex-biased ZRSR2 mutations in myeloid malignancies impair plasmacytoid dendritic cell activation and apoptosis","volume":"12","author":"Togami","year":"2022","journal-title":"Cancer Discov"},{"issue":"5","key":"2023082817145354300_bib19","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1182\/bloodadvances.2020003359","article-title":"Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis","volume":"5","author":"Renosi","year":"2021","journal-title":"Blood Adv"},{"issue":"7","key":"2023082817145354300_bib20","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41408-022-00699-1","article-title":"Integrative molecular profiling identifies two molecularly and clinically distinct subtypes of blastic plasmacytoid dendritic cell neoplasm","volume":"12","author":"K\u00fcnstner","year":"2022","journal-title":"Blood Cancer J"},{"issue":"22","key":"2023082817145354300_bib21","doi-asserted-by":"crossref","first-page":"19204","DOI":"10.18632\/oncotarget.4146","article-title":"Classification and clinical behavior of blastic plasmacytoid dendritic cell neoplasms according to their maturation-associated immunophenotypic profile","volume":"6","author":"Mart\u00edn-Mart\u00edn","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"2023082817145354300_bib22","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1365-2133.2009.09373.x","article-title":"Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice?","volume":"162","author":"Dalle","year":"2010","journal-title":"Br J Dermatol"},{"issue":"23","key":"2023082817145354300_bib23","article-title":"Biological description of 109 cases of blastic plasmacytoid dendritic cell neoplasm (BPDCN) from the French Network of BPDCN [abstract]","volume":"126","author":"Poret","year":"2015","journal-title":"Blood"},{"issue":"8","key":"2023082817145354300_bib24","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1182\/blood.2019001144","article-title":"Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark","volume":"134","author":"Taylor","year":"2019","journal-title":"Blood"},{"issue":"9","key":"2023082817145354300_bib25","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1080\/13543784.2018.1512970","article-title":"The advances in therapy of blastic plasmacytoid dendritic cell neoplasm","volume":"27","author":"Kerr","year":"2018","journal-title":"Expert Opin Invest Drugs"},{"issue":"5","key":"2023082817145354300_bib26","doi-asserted-by":"crossref","first-page":"890","DOI":"10.3904\/kjim.2015.406","article-title":"Clinical features and treatment outcomes of blastic plasmacytoid dendritic cell neoplasm: a single-center experience in Korea","volume":"32","author":"Kim","year":"2017","journal-title":"Kor J Intern Med"},{"issue":"3","key":"2023082817145354300_bib27","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.hoc.2020.01.011","article-title":"Chemotherapy options for blastic plasmacytoid dendritic cell neoplasm","volume":"34","author":"Haddadin","year":"2020","journal-title":"Hematol Oncol Clin N Am"},{"issue":"11","key":"2023082817145354300_bib28","first-page":"2603","article-title":"Sustained complete remission of a limited-stage blastic plasmacytoid dendritic cell neoplasm followed by a simultaneous combination of low-dose DeVIC therapy and radiation therapy: a case report and review of the literature","volume":"6","author":"Sugimoto","year":"2013","journal-title":"Int J Clin Exp Pathol"},{"issue":"2","key":"2023082817145354300_bib29","first-page":"150","article-title":"[Successful treatment with biweekly CHOP for bone marrow relapse of blastic plasmacytoid dendritic cell neoplasm]","volume":"58","author":"Ono","year":"2017","journal-title":"Rinsho Ketsueki"},{"issue":"10","key":"2023082817145354300_bib30","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1182\/bloodadvances.2021006645","article-title":"Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD","volume":"6","author":"Pemmaraju","year":"2022","journal-title":"Blood Adv"},{"issue":"23","key":"2023082817145354300_bib31","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1182\/blood-2015-01-621268","article-title":"Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm","volume":"125","author":"Aoki","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2023082817145354300_bib32","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.hoc.2020.01.009","article-title":"Hematopoietic cell transplant for blastic plasmacytoid dendritic cell neoplasm","volume":"34","author":"Kharfan-Dabaja","year":"2020","journal-title":"Hematol Oncol Clin N Am"},{"issue":"3","key":"2023082817145354300_bib33","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1182\/blood-2012-08-448613","article-title":"Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation","volume":"121","author":"Roos-Weil","year":"2013","journal-title":"Blood"},{"issue":"9","key":"2023082817145354300_bib34","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.3390\/cancers11091358","article-title":"CD123 as a therapeutic target in the treatment of hematological malignancies","volume":"11","author":"Testa","year":"2019","journal-title":"Cancers"},{"issue":"1","key":"2023082817145354300_bib35","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2050-7771-2-4","article-title":"123 is a membrane biomarker and a therapeutic target in hematologic malignancies","volume":"2","author":"Testa","year":"2014","journal-title":"Biomarker Res"},{"issue":"10","key":"2023082817145354300_bib36","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1097\/PAS.0000000000001316","article-title":"Dual expression of TCF4 and CD123 is highly sensitive and specific for blastic plasmacytoid dendritic cell neoplasm","volume":"43","author":"Sukswai","year":"2019","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"2023082817145354300_bib37","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.hoc.2020.01.004","article-title":"CD123 as a therapeutic target against malignant stem cells","volume":"34","author":"Sugita","year":"2020","journal-title":"Hematol Oncol Clin N Am"},{"issue":"16","key":"2023082817145354300_bib38","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.1182\/bloodadvances.2019000173","article-title":"Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm","volume":"4","author":"Pemmaraju","year":"2020","journal-title":"Blood Adv"},{"issue":"26","key":"2023082817145354300_bib39","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1200\/JCO.22.00034","article-title":"Long-term benefits of tagraxofusp for patients with blastic plasmacytoid dendritic cell neoplasm","volume":"40","author":"Pemmaraju","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2023082817145354300_bib40","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1038\/s41467-022-29669-8","article-title":"Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells","volume":"13","author":"Cai","year":"2022","journal-title":"Nat Commun"},{"issue":"11","key":"2023082817145354300_bib41","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.clml.2021.05.018","article-title":"Novel therapeutic approaches in blastic plasmacytoid dendritic cell neoplasm (BPDCN): era of targeted therapy","volume":"21","author":"Wilson","year":"2021","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"issue":"2","key":"2023082817145354300_bib42","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1200\/JCO.2010.30.5441","article-title":"Blastic plasmacytoid dendritic cell neoplasm","volume":"29","author":"Chen","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2023082817145354300_bib43","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1111\/jdv.16215","article-title":"Clinical diversity and treatment approaches to blastic plasmacytoid dendritic cell neoplasm: a Retrospective Multicentre Study","volume":"34","author":"Br\u00fcggen","year":"2020","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"15","key":"2023082817145354300_bib44","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1182\/blood.2021011817","article-title":"Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm","volume":"138","author":"Pemmaraju","year":"2021","journal-title":"Blood"},{"issue":"5","key":"2023082817145354300_bib45","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.ccell.2016.10.002","article-title":"A\u00a0druggable TCF4- and BRD4-dependent transcriptional network sustains malignancy in blastic plasmacytoid dendritic cell neoplasm","volume":"30","author":"Ceribelli","year":"2016","journal-title":"Cancer Cell"},{"issue":"23","key":"2023082817145354300_bib46","doi-asserted-by":"crossref","first-page":"5888","DOI":"10.3390\/cancers13235888","article-title":"Integrated clinical genotype-phenotype characteristics of blastic plasmacytoid dendritic cell neoplasm","volume":"13","author":"Yin","year":"2021","journal-title":"Cancers"},{"issue":"4","key":"2023082817145354300_bib47","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.3324\/haematol.2020.247569","article-title":"Immunophenotypic characterization of reactive and neoplastic plasmacytoid dendritic cells permits establishment of a 10-color flow cytometric panel for initial workup and residual disease evaluation of blastic plasmacytoid dendritic cell neoplasm","volume":"106","author":"Wang","year":"2021","journal-title":"Haematologica"},{"issue":"1","key":"2023082817145354300_bib48","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/10428194.2021.1975192","article-title":"CD303 (BDCA-2) - a potential novel target for therapy in hematologic malignancies","volume":"63","author":"Wilson","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"18","key":"2023082817145354300_bib49","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","article-title":"Clinical end points and response criteria in mycosis fungoides and s\u00e9zary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer","volume":"29","author":"Olsen","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"2023082817145354300_bib50","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41408-019-0262-0","article-title":"Features of non-activation dendritic state and immune deficiency in blastic plasmacytoid dendritic cell neoplasm (BPDCN)","volume":"9","author":"Beird","year":"2019","journal-title":"Blood Cancer J"},{"issue":"10","key":"2023082817145354300_bib51","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1182\/blood.2020007897","article-title":"Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia","volume":"137","author":"Xiao","year":"2021","journal-title":"Blood"},{"issue":"10","key":"2023082817145354300_bib52","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1182\/blood.2020008745","article-title":"Targeting the P-D-C: easy as C-D-1-2-3?","volume":"137","author":"Pemmaraju","year":"2021","journal-title":"Blood"},{"issue":"12","key":"2023082817145354300_bib53","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.3324\/haematol.2020.253740","article-title":"Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscape","volume":"106","author":"Zalma\u00ef","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"2023082817145354300_bib54","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/cyto.b.21761","article-title":"Flow cytometry identifies a spectrum of maturation in myeloid neoplasms having plasmacytoid dendritic cell differentiation","volume":"98","author":"Hamadeh","year":"2020","journal-title":"Cytometry B Clin Cytometry"},{"issue":"3","key":"2023082817145354300_bib55","first-page":"333","article-title":"Myeloid sarcoma with CBFB-MYH11 fusion (Inv(16) or t(16;16)) prevails in the abdomen","volume":"153","author":"Dalland","year":"2020","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"2023082817145354300_bib56","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/cyto.a.23953","article-title":"Myeloid neoplasms with elevated plasmacytoid dendritic cell differentiation reflect the maturation process of dendritic cells","volume":"97","author":"Huang","year":"2020","journal-title":"Cytometry A"},{"issue":"14","key":"2023082817145354300_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14143375","article-title":"Immunophenotypic and molecular features of acute myeloid leukemia with plasmacytoid dendritic cell differentiation are distinct from blastic plasmacytoid dendritic cell neoplasm","volume":"14","author":"Wang","year":"2022","journal-title":"Cancers"},{"issue":"11","key":"2023082817145354300_bib58","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1600-0560.2011.01777.x","article-title":"Cutaneous accumulation of plasmacytoid dendritic cells associated with acute myeloid leukemia: a rare condition distinct from blastic plasmacytoid dendritic cell neoplasm","volume":"38","author":"Dargent","year":"2011","journal-title":"J\u00a0Cutan Pathol"},{"issue":"5","key":"2023082817145354300_bib59","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/00000478-200405000-00004","article-title":"Nodal and extranodal tumor-forming accumulation of plasmacytoid monocytes\/interferon-producing cells associated with myeloid disorders","volume":"28","author":"Vermi","year":"2004","journal-title":"Am J Surg Pathol"},{"issue":"11","key":"2023082817145354300_bib60","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1038\/s41375-021-01228-y","article-title":"Divergent clonal evolution of blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia from a shared TET2-mutated origin","volume":"35","author":"Batta","year":"2021","journal-title":"Leukemia"},{"issue":"6","key":"2023082817145354300_bib61","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1182\/bloodadvances.2019001260","article-title":"Comprehensive metagenomic analysis of blastic plasmacytoid dendritic cell neoplasm","volume":"4","author":"Nomburg","year":"2020","journal-title":"Blood Adv"},{"issue":"10","key":"2023082817145354300_bib62","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1080\/21645515.2020.1788299","article-title":"Targeting the alpha subunit of IL-3 receptor (CD123) in patients with acute leukemia","volume":"16","author":"Aldoss","year":"2020","journal-title":"Hum Vaccines Immunother"},{"issue":"2","key":"2023082817145354300_bib63","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1432-1033.1980.tb04438.x","article-title":"Increased toxicity of diphtheria toxin for human lymphoblastoid cells following covalent linkage to anti-(human lymphocyte) globulin or its F(Ab\u2019)2 fragment","volume":"104","author":"Ross","year":"1980","journal-title":"Eur J Biochem"},{"issue":"5647","key":"2023082817145354300_bib64","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/271752a0","article-title":"Toxicity of diphtheria toxin for lymphoblastoid cells is increased by conjugation to antilymphocytic globulin","volume":"271","author":"Thorpe","year":"1978","journal-title":"Nature"},{"issue":"3","key":"2023082817145354300_bib65","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1182\/blood-2014-06-578633","article-title":"Targeted diphtheria toxin to treat BPDCN","volume":"124","author":"FitzGerald","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2023082817145354300_bib66","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/asheducation-2016.1.16","article-title":"Treatment of blastic plasmacytoid dendritic cell neoplasm","volume":"2016","author":"Sullivan","year":"2016","journal-title":"Hematology"},{"key":"2023082817145354300_bib67","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.3389\/fmicb.2019.02340","article-title":"Targeted diphtheria toxin-based therapy: a review article","volume":"10","author":"Shafiee","year":"2019","journal-title":"Front Microbiol"},{"issue":"2","key":"2023082817145354300_bib68","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3324\/haematol.2014.111740","article-title":"In\u00a0vivo and in\u00a0vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent","volume":"100","author":"Angelot-Delettre","year":"2015","journal-title":"Haematologica"},{"issue":"3","key":"2023082817145354300_bib69","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1182\/blood-2014-04-566737","article-title":"Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients","volume":"124","author":"Frankel","year":"2014","journal-title":"Blood"},{"issue":"17","key":"2023082817145354300_bib70","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1056\/NEJMoa1815105","article-title":"Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm","volume":"380","author":"Pemmaraju","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"2023082817145354300_bib71","first-page":"3032","article-title":"Long-term benefits of tagraxofusp for patients with blastic plasmacytoid dendritic cell neoplasm","volume":"40","author":"Pemmaraju","year":"2022","journal-title":"J\u00a0Clin Orthod"},{"issue":"14","key":"2023082817145354300_bib72","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1182\/bloodadvances.2020001875","article-title":"Survival outcomes in blastic plasmacytoid dendritic cell neoplasm by first-line treatment and stem cell transplant","volume":"4","author":"Yun","year":"2020","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2023082817145354300_bib73","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2020-139903","article-title":"Clinical profile of IMGN632, a novel CD123-targeting antibody-drug conjugate (ADC), in patients with relapsed\/refractory (R\/R) blastic plasmacytoid dendritic cell neoplasm (BPDCN)","volume":"136","author":"Pemmaraju","year":"2020","journal-title":"Blood"},{"issue":"3","key":"2023082817145354300_bib74","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.hoc.2020.01.006","article-title":"Immunotherapies targeting CD123 for blastic plasmacytoid dendritic cell neoplasm","volume":"34","author":"Xue","year":"2020","journal-title":"Hematol Oncol Clin N Am"},{"issue":"3","key":"2023082817145354300_bib75","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ajh.25000","article-title":"Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies","volume":"93","author":"DiNardo","year":"2018","journal-title":"Am J Hematol"},{"issue":"1","key":"2023082817145354300_bib76","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"2","key":"2023082817145354300_bib77","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1158\/2159-8290.CD-16-0999","article-title":"Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to venetoclax","volume":"7","author":"Montero","year":"2017","journal-title":"Cancer Discov"},{"issue":"15","key":"2023082817145354300_bib78","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1056\/NEJMc1808354","article-title":"Venetoclax in a patient with a blastic plasmacytoid dendritic-cell neoplasm","volume":"379","author":"Agha","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"51","key":"2023082817145354300_bib79","doi-asserted-by":"crossref","first-page":"e9452","DOI":"10.1097\/MD.0000000000009452","article-title":"Novel treatment of blastic plasmacytoid dendritic cell neoplasm: a case report","volume":"96","author":"Grushchak","year":"2017","journal-title":"Medicine"},{"issue":"1","key":"2023082817145354300_bib80","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s12288-020-01313-9","article-title":"Blastic plasmacytoid dendritic cell neoplasm: single center experience on a rare hematological malignancy","volume":"37","author":"Narli Ozdemir","year":"2021","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"7","key":"2023082817145354300_bib81","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1056\/NEJMc1814963","article-title":"More on blastic plasmacytoid dendritic-cell neoplasms","volume":"380","author":"Pemmaraju","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2023082817145354300_bib82","first-page":"145","article-title":"Venetoclax-based therapies for acute myeloid leukemia. best practice & research","volume":"32","author":"Guerra","year":"2019","journal-title":"Clin Haematol"},{"issue":"13","key":"2023082817145354300_bib83","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1158\/1078-0432.CCR-19-1900","article-title":"5-azacitidine induces NOXA to prime AML cells for venetoclax-mediated apoptosis","volume":"26","author":"Jin","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2023082817145354300_bib84","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1177\/1078155220951850","article-title":"Tagraxofusp followed by combined azacitidine and venetoclax in blastic plasmacytoid dendritic cell neoplasm: a case report and literature review","volume":"27","author":"Samhouri","year":"2021","journal-title":"J\u00a0Oncol Pharm Pract"},{"issue":"2","key":"2023082817145354300_bib85","doi-asserted-by":"crossref","first-page":"E62","DOI":"10.1002\/ajh.26417","article-title":"Venetoclax and hypomethylating agents in older\/unfit patients with blastic plasmacytoid dendritic cell neoplasm","volume":"97","author":"Gangat","year":"2022","journal-title":"Am J Hematol"},{"issue":"1","key":"2023082817145354300_bib86","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2991\/chi.d.190218.001","article-title":"Therapeutic approaches for blastic plasmacytoid dendritic cell neoplasm: allogeneic hematopoietic cell transplantation and novel therapies","volume":"1","author":"Kharfan-Dabaja","year":"2019","journal-title":"Clin Hematol Int"},{"issue":"3","key":"2023082817145354300_bib87","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"issue":"9","key":"2023082817145354300_bib88","doi-asserted-by":"crossref","first-page":"e432","DOI":"10.3324\/haematol.2018.214635","article-title":"Daratumumab for treatment of blastic plasmacytoid dendritic cell neoplasm. a single-case report","volume":"104","author":"Iversen","year":"2019","journal-title":"Haematologica"},{"issue":"4","key":"2023082817145354300_bib89","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/hon.2671","article-title":"The lenalidomide\/bortezomib\/dexamethasone regimen for the treatment of blastic plasmacytoid dendritic cell neoplasm","volume":"37","author":"Marmouset","year":"2019","journal-title":"Hematol Oncol"},{"issue":"6","key":"2023082817145354300_bib90","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1007\/s00277-019-03623-z","article-title":"Clinical efficacy of bortezomib and lenalidomide in blastic plasmacytoid dendritic cell neoplasm","volume":"98","author":"Yang","year":"2019","journal-title":"Ann Hematol"},{"issue":"9","key":"2023082817145354300_bib91","doi-asserted-by":"crossref","first-page":"10174","DOI":"10.18632\/oncotarget.7101","article-title":"Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy","volume":"7","author":"Mart\u00edn-Mart\u00edn","year":"2016","journal-title":"Oncotarget"},{"issue":"11","key":"2023082817145354300_bib92","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1080\/10428194.2022.2090552","article-title":"Treatment patterns and outcomes of patients with CNS involvement of blastic plasmacytoid dendritic cell neoplasm (BPDCN)","volume":"63","author":"Davis","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"2023082817145354300_bib93","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.clml.2018.07.295","article-title":"Allogeneic hematopoietic cell transplantation is an effective treatment for blastic plasmacytoid dendritic cell neoplasm in first complete remission: systematic review and meta-analysis","volume":"18","author":"Kharfan-Dabaja","year":"2018","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"issue":"5","key":"2023082817145354300_bib94","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/bjh.14954","article-title":"Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American Multicentre Collaborative Study","volume":"179","author":"Kharfan-Dabaja","year":"2017","journal-title":"Br J Haematol"},{"issue":"3","key":"2023082817145354300_bib95","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1080\/10428194.2020.1842399","article-title":"Bromodomain and extra-terminal (BET) inhibitors in treating myeloid neoplasms","volume":"62","author":"Chen","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"2023082817145354300_bib96","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1038\/s41375-018-0154-5","article-title":"Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug\u00a0response","volume":"32","author":"Sakamoto","year":"2018","journal-title":"Leukemia"},{"issue":"15 suppl","key":"2023082817145354300_bib97","doi-asserted-by":"crossref","first-page":"TPS7564","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS7564","article-title":"A\u00a0phase Ib\/II study of the CD123-targeting antibody-drug conjugate IMGN632 as monotherapy or in combination with venetoclax and\/or azacitidine for patients with CD123-positive acute myeloid leukemia","volume":"38","author":"Daver","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"2023082817145354300_bib98","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1182\/bloodadvances.2018016378","article-title":"Evaluating measurable residual disease in acute myeloid leukemia","volume":"2","author":"Ravandi","year":"2018","journal-title":"Blood Adv"},{"issue":"6","key":"2023082817145354300_bib99","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41375-021-01230-4","article-title":"Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations","volume":"35","author":"Walter","year":"2021","journal-title":"Leukemia"},{"issue":"4","key":"2023082817145354300_bib100","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1200\/JCO.2008.18.6130","article-title":"Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin","volume":"27","author":"Ravandi","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2023082817145354300_bib101","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41408-021-00514-3","article-title":"Acute\u00a0promyelocytic leukemia current treatment algorithms","volume":"11","author":"Yilmaz","year":"2021","journal-title":"Blood Cancer J"},{"issue":"12","key":"2023082817145354300_bib102","doi-asserted-by":"crossref","first-page":"4658","DOI":"10.1182\/blood-2005-11-4590","article-title":"Eradication of minimal residual disease in hairy cell leukemia","volume":"107","author":"Ravandi","year":"2006","journal-title":"Blood"},{"issue":"1","key":"2023082817145354300_bib103","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-020-01004-y","article-title":"Moxetumomab pasudotox in heavily pre-treated patients with relapsed\/refractory hairy cell leukemia (HCL): long-term follow-up from the Pivotal Trial","volume":"14","author":"Kreitman","year":"2021","journal-title":"J\u00a0Hematol Oncol"},{"issue":"24","key":"2023082817145354300_bib104","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1056\/NEJMoa1014209","article-title":"BRAF mutations in hairy-cell leukemia","volume":"364","author":"Tiacci","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2023082817145354300_bib105","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/s41375-022-01538-9","article-title":"Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly patients","volume":"36","author":"Khanlari","year":"2022","journal-title":"Leukemia"},{"key":"2023082817145354300_bib106","doi-asserted-by":"crossref","first-page":"809414","DOI":"10.3389\/fimmu.2022.809414","article-title":"Single-cell multiomics reveals clonal T-cell expansions and exhaustion in blastic plasmacytoid dendritic cell neoplasm","volume":"13","author":"DePasquale","year":"2022","journal-title":"Front Immunol"},{"issue":"9","key":"2023082817145354300_bib107","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1080\/10428194.2020.1755856","article-title":"Evidence for separate transformation to acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm from a shared ancestral hematopoietic clone","volume":"61","author":"Luskin","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2023082817145354300_bib108","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1200\/JCO.21.01595","article-title":"CD123 expression is associated with high-risk disease characteristics in childhood acute myeloid leukemia: a report from the Children\u2019s Oncology Group","volume":"40","author":"Lamble","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2023082817145354300_bib109","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/gcc.20500","article-title":"Identification of genes with abnormal expression changes in acute myeloid leukemia","volume":"47","author":"Stirewalt","year":"2008","journal-title":"Gene Chromosome Cancer"},{"issue":"3","key":"2023082817145354300_bib110","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.hoc.2020.01.008","article-title":"Blastic plasmacytoid dendritic cell neoplasm in children","volume":"34","author":"Li","year":"2020","journal-title":"Hematol Oncol Clin N Am"},{"issue":"3","key":"2023082817145354300_bib111","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1158\/1078-0432.CCR-19-2329","article-title":"FDA approval summary: tagraxofusp-erzs for treatment of blastic plasmacytoid dendritic cell neoplasm","volume":"26","author":"Jen","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2023082817145354300_bib112","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-018-0604-6","article-title":"First pediatric experience of SL-401, a CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm: report of three cases","volume":"11","author":"Sun","year":"2018","journal-title":"J\u00a0Hematol Oncol"},{"key":"2023082817145354300_bib113","first-page":"357383","article-title":"Treatment of blastic plasmacytoid dendritic cell neoplasm in pediatric patients with tagraxofusp, a CD123-targeted therapy","author":"Pemmaraju","year":"2021","journal-title":"European Hematol Assoc"},{"key":"2023082817145354300_bib114","doi-asserted-by":"crossref","first-page":"100313","DOI":"10.1016\/j.lrr.2022.100313","article-title":"Hyper-CVAD combined with venetoclax for relapsed pediatric blastic plasmacytoid dendritic cell neoplasm (BPDCN): A case report and literature review","author":"Abla","year":"2022","journal-title":"Leukemia research reports"},{"issue":"9","key":"2023082817145354300_bib115","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1080\/10428194.2021.1901096","article-title":"Myeloproliferative neoplasm questionnaire: assessing patient disease knowledge in the modern digital information era","volume":"62","author":"Pemmaraju","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2023082817145354300_bib116","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12885-016-2208-2","article-title":"Myeloproliferative neoplasms (MPNs) have a significant impact on patients\u2019 overall health and productivity: the MPN Landmark Survey","volume":"16","author":"Mesa","year":"2016","journal-title":"BMC Cancer"},{"issue":"10","key":"2023082817145354300_bib117","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1007\/s00277-017-3082-y","article-title":"The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the International MPN Landmark Survey","volume":"96","author":"Harrison","year":"2017","journal-title":"Ann Hematol"},{"issue":"8","key":"2023082817145354300_bib118","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12082202","article-title":"Body mass index and total symptom burden in myeloproliferative neoplasms discovery of a U-shaped association","volume":"12","author":"Christensen","year":"2020","journal-title":"Cancers"},{"issue":"1","key":"2023082817145354300_bib119","first-page":"54","article-title":"Neoplasia bl\u00e1stica de c\u00e9lulas dendr\u00edticas plasmocitoides","volume":"12","author":"Nambo-Lucio","year":"2013","journal-title":"Gac Mex Oncol"},{"issue":"10","key":"2023082817145354300_bib120","first-page":"5281","article-title":"A\u00a0new palliative treatment for blastic plasmacytoid dendritic cell neoplasm: a case report and review of the literature","volume":"47","author":"Yang","year":"2019","journal-title":"J\u00a0Int Med Res"},{"issue":"19","key":"2023082817145354300_bib121","doi-asserted-by":"crossref","first-page":"4838","DOI":"10.1182\/bloodadvances.2020002474","article-title":"Blastic plasmacytoid dendritic cell neoplasms: results of an international survey on 398 adult patients","volume":"4","author":"Laribi","year":"2020","journal-title":"Blood Adv"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/141\/6\/567\/2075085\/blood_bld-2022-017865-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/141\/6\/567\/2075085\/blood_bld-2022-017865-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T13:15:51Z","timestamp":1693228551000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/141\/6\/567\/493283\/North-American-Blastic-Plasmacytoid-Dendritic-Cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,9]]},"references-count":121,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,2,9]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2022017865","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,9]]}}}